Department of Oncology, University of Torino at San Luigi University Hospital, Orbassano, Italy.
Department of Oncology, University of Torino, Turin, Italy.
In Vivo. 2019 Nov-Dec;33(6):2021-2026. doi: 10.21873/invivo.11699.
BACKGROUND/AIM: Double diagnosis of lung cancer (LC) and ovarian cancer (OC) is rare. Here, we describe patients with synchronous/metachronous LC and OC to identify common clinical and pathological patterns.
Clinical, pathological and molecular data of patients diagnosed and treated at 30 European Institutions from 2008 to 2018 were retrieved and analysed. Whenever tissue was available, centralized pathology revision was performed.
A total of 19 cases were found; one was excluded at pathology revision. Most LCs were adenocarcinomas (15/18) and most OCs were high-grade serous (15/18) carcinomas. Of the 9 patients analysed, 7 carried oncogene-addicted LC (4 EGFR, 1 B-RAF and 2 ALK) and five out of 7 carried BRCA mutations. One patient with a germline-BRCA1 mutation received olaparib, resulting in a durable response of both malignancies. Median overall survival was 33 months.
In our series, most synchronous/metachronous LCs and OCs showed genetic alterations. Further analyses with wide NGS panel could shed light on the biological mechanisms driving their occurrence.
背景/目的：肺癌（LC）和卵巢癌（OC）的双重诊断较为罕见。在此，我们描述了同时/异时性 LC 和 OC 的患者，以确定常见的临床和病理模式。
检索并分析了 2008 年至 2018 年间在 30 个欧洲机构诊断和治疗的患者的临床、病理和分子数据。只要有组织，就进行集中的病理复查。
共发现 19 例，1 例在病理复查时被排除。大多数 LC 是腺癌（15/18），大多数 OC 是高级别浆液性（15/18）癌。在分析的 9 名患者中，7 名患有依赖致癌基因的 LC（4 名 EGFR、1 名 B-RAF 和 2 名 ALK），其中 5 名携带 BRCA 突变。1 名携带胚系-BRCA1 突变的患者接受奥拉帕利治疗，两种恶性肿瘤均获得持久缓解。中位总生存期为 33 个月。
在我们的研究中，大多数同时/异时性 LC 和 OC 显示存在遗传改变。进一步进行广泛的 NGS 面板分析可以揭示驱动其发生的生物学机制。
